NeoGenomics NEO Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| NET REVENUE by Product | ||||||
| Client direct billing | $528.41M+1.8% | $518.84M+2.0% | $508.79M+2.1% | $498.15M+2.6% | $485.29M+2.1% | |
| Commercial insurance | $123.59M+5.2% | $117.51M+4.2% | $112.82M+7.4% | $105.02M+3.9% | $101.1M+1.3% | |
| Medicare and other government | $93.91M+3.3% | $90.87M+4.2% | $87.2M+2.0% | $85.52M+0.2% | $85.33M+0.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does NeoGenomics break its business down?
- NeoGenomics (NEO) reports net revenue by product across 4 parts — Client direct billing, Commercial insurance, Medicare and other government and Self-pay. Each is extracted from the segment footnotes and tracked over time.
- Where does NeoGenomics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in NeoGenomics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
